Peyto Exploration & Development (TSE:PEY) First Quarter 2025 Results Key Financial Results Revenue: CA$347.3m (up 38% from 1Q 2024). Net income: CA$114.1m (up 14% from 1Q 2024). Profit margin: 33% (down from 40% in 1Q 2024). The decrease in margin was driven by higher …
(Reuters) -Deere & Co cut the lower end of its annual profit forecast and reported a fall in second-quarter results on Thursday due to economic uncertainty and softer demand for its tractors from farmers opting to rent machines instead. Farmers facing high interest rates …
XI’AN, China, May 15, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) (“BON” or the “Company”), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, announced today that it will effect a 1-for-25 reverse stock split …
Record-high backlog Record-high Nuclear quarterly revenue and Segment Adjusted EBIT MONTREAL, May 15, 2025 /CNW/ - AtkinsRéalis Group Inc. (TSX: ATRL), a world-class engineering services and nuclear company with offices around the world, today announced its financial results for the first quarter ended March …
Easy-to-Use Tech Preserves Photos, Documents and Awards to Pay Tribute to Veterans and Share Memories LOS ALAMITOS, Calif., May 15, 2025 /PRNewswire/ -- As loved ones prepare to gather this Memorial Day to honor those who have served the nation, they often seek meaningful …
Key Points Energy Transfer is an infrastructure company whose growth ambitions fit the current administration's plans. Clean energy specialist Clearway Energy has flourished in 2025, and offers a forward dividend yield of 6.1%. Starbucks has lost over a quarter of its value in just …
Fate Therapeutics (NASDAQ:FATE) First Quarter 2025 Results Key Financial Results Revenue: US$1.63m (down 15% from 1Q 2024). Net loss: US$37.6m (loss narrowed by 22% from 1Q 2024). US$0.32 loss per share (improved from US$0.47 loss in 1Q 2024). We've discovered 3 warning signs about …
CAE (TSE:CAE) Full Year 2025 Results Key Financial Results Revenue: CA$4.71b (up 9.9% from FY 2024). Net income: CA$405.3m (up from CA$325.3m loss in FY 2024). Profit margin: 8.6% (up from net loss in FY 2024). The move to profitability was primarily driven by …
BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the launch of an underwritten public offering of shares of its common stock and …
By David Bautz, PhDNASDAQ:ARWRREAD THE FULL ARWR RESEARCH REPORT Business Update Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has a robust pipeline of RNA interference (RNAi) therapies utilizing the company’s TRiM™ platform. The TRiM platform allows for targeting of RNAi therapeutics to seven different cell types, including …